<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05614700</url>
  </required_header>
  <id_info>
    <org_study_id>21/YH/0305</org_study_id>
    <nct_id>NCT05614700</nct_id>
  </id_info>
  <brief_title>Prostate Reirradiation Toxicity Outcomes Feasibility Study</brief_title>
  <acronym>RO-PIP</acronym>
  <official_title>Reirradiation Options for Previously Irradiated Prostate Cancer (RO-PIP): Feasibility Randomised Clinical Trial Investigating Toxicity Outcomes Following Reirradiation With Ultra-hypofractionated External Beam Radiotherapy vs. High Dose Rate Brachytherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leeds</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RO-PIP trial aims to determine the feasibility of recruitment to a trial randomising&#xD;
      patients to salvage ultra-hypofractionated external beam radiotherapy or high dose rate&#xD;
      brachytherapy and provide prospective data on patient recorded toxicity outcomes that will&#xD;
      inform a future phase III trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiotherapy is the most common curative treatment for non-metastatic prostate cancer,&#xD;
      however up to 13% of patients will develop local recurrence within 10 years. Patients can&#xD;
      undergo further and potentially curative treatment including salvage surgery, brachytherapy&#xD;
      (BT), external beam radiotherapy (EBRT), high intensity focused ultrasound and cryotherapy.&#xD;
      Systematic review shows that high dose rate (HDR) BT and stereotactic body radiotherapy&#xD;
      (SBRT) have the best outcomes in terms of biochemical control and lowest side effects. The&#xD;
      RO-PIP trial aims to determine the feasibility of recruitment to a trial randomising patients&#xD;
      to salvage HDR-BT or SBRT and provide prospective data on patient recorded toxicity outcomes&#xD;
      that will inform a future phase III trial.&#xD;
&#xD;
      The primary endpoint of the RO-PIP feasibility study is to evaluate the patient recruitment&#xD;
      potential over 2 years to a trial randomising to either SBRT or HDR-BT for patients who&#xD;
      develop local recurrence of prostate cancer following previous radiation therapy. The aim is&#xD;
      to recruit 60 patients across 3 sites over 2 years and randomise 1:1 to SBRT or HDR-BT.&#xD;
      Secondary objectives include recording clinician and patient reported outcome measures&#xD;
      (PROMs) to evaluate treatment-related toxicity. In addition, the study aims to identify&#xD;
      potential imaging, genomic and proteomic biomarkers that are predictive of toxicity and&#xD;
      outcome based on hypoxia status, a prognostic marker of prostate cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2022</start_date>
  <completion_date type="Anticipated">November 15, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised Feasibility Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Feasibility</measure>
    <time_frame>24 months</time_frame>
    <description>Recruitment rates for the whole 24-month recruitment period will be reported overall and per recruiting site. The average recruitment rate per month and in total over the formal monitoring period will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Toxicity</measure>
    <time_frame>0-3 months and &gt;3 months</time_frame>
    <description>Incidence of patient reported acute (0-3 months) and long-term toxicity (&gt;3 months) and impact on QoL determined by EPIC-26 (prostate cancer related QoL and functional outcomes), EORTC QLQ-C30 (general QoL score) and international prostate symptom score (IPSS) (urinary and sexual functional outcomes) measurements (Key secondary endpoint).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician Reported Toxicity</measure>
    <time_frame>0-3 months and &gt;3 months</time_frame>
    <description>Incidence of clinician-reported treatment toxicity as per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Imaging biomarkers</measure>
    <time_frame>1 month and 12 months</time_frame>
    <description>MRI biomarkers at 1 month and 1 year post-treatment predictive of toxicity based on PROMs.</description>
  </other_outcome>
  <other_outcome>
    <measure>Imaging Reproducibility</measure>
    <time_frame>Baseline, 1 and 12 months</time_frame>
    <description>Multiple measures of image quality and reproducibility of prostate functional imaging (e.g. diffusion coefficient values from IVIM sequences) for measuring tumour biology will be summarised.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypoxia Gene Signature</measure>
    <time_frame>Baseline</time_frame>
    <description>Hypoxia levels based on a hypoxia associated gene signature obtained from the pre-salvage RT biopsy correlated with MRI biomarkers.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proteomic Biomarkers</measure>
    <time_frame>Baseline, 1, 3 and 6 months</time_frame>
    <description>Changes in the levels of inflammatory cytokine signatures from urine and blood obtained at baseline and after reirradiation in relation to PROMs.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Radiotherapy Side Effect</condition>
  <arm_group>
    <arm_group_label>High dose-rate brachytherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two HDR-BT treatment schedules, either a single fraction 19Gy treatment or 27Gy in 2 fractions approximately 2 weeks apart will be used to be decided by treating centre.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultra-hypofractionated external beam radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 5 fractions of 7.25Gy per fraction which will be delivered alternate days over no more than 2 weeks to provide a total dose of 36.25Gy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brachytherapy</intervention_name>
    <description>High Dose-Rate Brachytherapy</description>
    <arm_group_label>High dose-rate brachytherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Sterotactic Body Radiotherapy</intervention_name>
    <description>Hypofractionated External Beam Radiotherapy</description>
    <arm_group_label>Ultra-hypofractionated external beam radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male individuals aged over 18 years&#xD;
&#xD;
          -  Histologically confirmed locally recurrent prostate cancer (following previous&#xD;
             radiotherapy no less than 2 years ago)&#xD;
&#xD;
          -  No metastatic disease&#xD;
&#xD;
          -  Able and willing to provide an informed consent to participate&#xD;
&#xD;
          -  World Health Organisation (WHO) performance status 0-2&#xD;
&#xD;
          -  Reasonable urinary function (IPSS &lt; 20 and Qmax &gt; 10 ml/second on flow tests)&#xD;
&#xD;
          -  Greater than 10 year life expectancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are unfit for a general anaesthetic due to other comorbidities&#xD;
&#xD;
          -  Clinical or radiological evidence of metastatic prostate disease&#xD;
&#xD;
          -  Any patient with a medical or psychiatric condition that impairs their ability to give&#xD;
             informed consent&#xD;
&#xD;
          -  Contraindication or intolerance of magnetic resonance scanning&#xD;
&#xD;
          -  Prior prostatectomy&#xD;
&#xD;
          -  History of inflammatory bowel disease.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Henry</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leeds</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann Henry</last_name>
    <phone>0113 2067630</phone>
    <email>a.henry@leeds.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jim Zhong</last_name>
    <phone>0113 2067630</phone>
    <email>j.zhong@leeds.ac.uk</email>
  </overall_contact_backup>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 1, 2022</study_first_submitted>
  <study_first_submitted_qc>November 5, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leeds</investigator_affiliation>
    <investigator_full_name>Ann Henry</investigator_full_name>
    <investigator_title>Associate Professor in Clinical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

